Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists-Reference-Cited by-同舟云学术

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

Published:2015-09 Issue:7569 Volume:525 Page:380-383
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Prost Stéphane,Relouzat Francis,Spentchian Marc,Ouzegdouh Yasmine,Saliba Joseph,Massonnet Gérald,Beressi Jean-Paul,Verhoeyen Els,Raggueneau Victoria,Maneglier Benjamin,Castaigne Sylvie,Chomienne Christine,Chrétien Stany,Rousselot Philippe,Leboulch Philippe

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature15248.pdf

Reference36 articles.

1. Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nature Rev. Cancer 12, 133–143 (2012)

2. Chomel, J. C. & Turhan, A. G. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2, 713–727 (2011)

3. de Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358–3363 (2008)

4. Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396–409 (2011)

5. Hu, C. J., Sataur, A., Wang, L., Chen, H. & Simon, M. C. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell 18, 4528–4542 (2007)

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel targeted therapies in chronic myeloid leukemia;Pharmaceutical Science Advances;2024-09

2. Cancer stem cells: advances in knowledge and implications for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-05

3. Dual function of activated PPARγ by ligands on tumor growth and immunotherapy;Medical Oncology;2024-04-15

4. Exploring the nexus of nuclear receptors in hematological malignancies;Cellular and Molecular Life Sciences;2024-02-09

5. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors;Expert Opinion on Pharmacotherapy;2024-01-22